We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease, also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically hig... Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease, also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard. Show more
Lucid Diagnostics Closes Series B / B-1 Preferred Stock Offering and Appoints Healthcare Industry Veteran Dennis Matheis to Board of Directors PR Newswire NEW YORK, May 7, 2024 Final closing...
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 13, 2024 PR Newswire NEW YORK, May 2, 2024 Conference Call and Webcast at 8:30AM Eastern Time NEW YORK, May 2, 2024...
Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Data from National Cancer Institute-Sponsored, Prospective, Multicenter Clinical Validation Study of EsoGuard® Esophageal...
Lucid Diagnostics Partners with the Esophageal Cancer Action Network (ECAN) to Highlight Esophageal Cancer Awareness Month PR Newswire NEW YORK, April 29, 2024 NEW YORK, April 29, 2024...
Lucid Diagnostics to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference PR Newswire NEW YORK, April 8, 2024 NEW YORK, April 8, 2024 /PRNewswire/ -- Lucid...
PAVmed Provides Business Update and Fourth Quarter and Full Year 2023 Financial Results PR Newswire NEW YORK, March 26, 2024 Lucid's quarterly revenue increased 33 percent sequentially Launched...
Lucid Diagnostics Provides Business Update and Preliminary Fourth Quarter and Full Year 2023 Financial Results PR Newswire NEW YORK, March 25, 2024 Quarterly EsoGuard® revenue increased 33...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.291 | 36.8821292776 | 0.789 | 1.07 | 0.7467 | 421238 | 0.95011692 | CS |
| 4 | 0.16 | 17.3913043478 | 0.92 | 1.07 | 0.6301 | 243715 | 0.84947427 | CS |
| 12 | -0.14 | -11.4754098361 | 1.22 | 1.4 | 0.6301 | 219246 | 0.99204057 | CS |
| 26 | -0.19 | -14.9606299213 | 1.27 | 1.58 | 0.6301 | 126310 | 1.06383778 | CS |
| 52 | -0.49 | -31.2101910828 | 1.57 | 1.85 | 0.6301 | 87059 | 1.17126271 | CS |
| 156 | -11.67 | -91.5294117647 | 12.75 | 13.5 | 0.6301 | 122437 | 3.54286212 | CS |
| 260 | -11.67 | -91.5294117647 | 12.75 | 13.5 | 0.6301 | 122437 | 3.54286212 | CS |
Monksdream
2 months ago
Monksdream
7 months ago
ErnieBilco
2 years ago
makinezmoney
2 years ago
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
